Health-Food and Development website is produced by the PPM-Confirel Group

PPM and Labiocert at CPHI South East Asia in Malaysia

Publish date: 08 August 2025 / Health / Author : admin

CPHI South East Asia 2025 took place from July 16 to 18, 2025, at the MITEC in Kuala Lumpur, Malaysia, bringing together over 8,000 pharmaceutical sector professionals, including PPM and Labiocert Laboratories, and 400 exhibitors from Asia and around the world.

“CPHI South East Asia,” meaning “Convention on Pharmaceutical Ingredients,” is an international event held in various regions (Europe, China, India, Japan, etc.), serving as a major platform uniting all segments of the pharmaceutical supply chain: manufacturers, raw material suppliers, service providers, packaging, technological innovation, and laboratories.

During the three days in Kuala Lumpur, over forty seminars and conferences enabled experts to debate major sector trends such as the growth of active pharmaceutical ingredients (APIs), the rise of CROs (contract research organizations), the increasing digitalization of the value chain, as well as challenges relating to pharmaceutical packaging. Special focus was given to Southeast Asian markets—Indonesia, Thailand, Vietnam, the Philippines, and Malaysia—whose dynamism and recent reforms attract foreign investors and foster industrial innovation.

The event also served as a venue for many business and networking sessions. Companies seized new opportunities by meeting partners, distributors, technology providers, policymakers, and investors, in a context where the regional pharmaceutical sector is experiencing sustained growth, estimated at over 6% annually, and could reach 18.27 billion dollars by 2030.

Multiple geopolitical and industrial issues fueled the debates: the rise of Malaysia as a regional hub, supported by attractive fiscal policies and openness to foreign investment; local development of pharmaceutical manufacturing, particularly production of active ingredients and finished products; and the growing appeal of the region for Indian, Chinese, Japanese, and also European and American actors. The rapidly growing CRO and clinical trial sector benefits from a skilled workforce and an ever-improving regulatory environment. Environmental considerations, as well as the acceleration of digitalization, have now become priorities in the sector’s expansion strategies.